Changes of intracardiac hemodynamics in patients with decreased myocardial contractility at transplantation of cord blood stem cells
Abstract
Experiments on animals have shown an effectiveness of cord blood stem cells (SCs) in restoration of myocardial contractility. But there is not enough information about the use of this SCs type at heart lesion in people. Therefore, the aim of this study was to analyze the effect of cord blood SCs transplantation on impaired myocardial contractility of patients with chronic heart failure.
Materials and methods. According to the data echocardiography we analyzed the changes of intracardiac hemodynamics in patients with decreased myocardial contractility, who underwent intravenous transplantation of cord blood stem cells in case of ineffective traditional conservative therapy schemes of heart failure (HF).
Results. Left ventricular ejection fraction before cord blood stem cells transplantation was 22.0 ± 5.0 %, 1 month after SC transplantation – 22.3 ± 6.5%, and in 3 months – 28.5 ± 7.8 % (p < 0.05). The average stroke index increased from 21.3 ± 3.5 ml/m2 before transplantation up to 29.0 ± 8.5 ml/m2 3 months after transplantation SC (p < 0.05). Statistically significant changes of diastolic function parameters (index e’, E/A, E/e’) and venous stasis have not been established. Before transplantation local cell contractility index (LCI) of basal and middle segments was 2.43 points; 1 month after transplantation LCI decreased to 2.38, and after 3 months – up to 2.18 points (p <0.05).
Conclusion. In a short term (1-3 months) after transplantation of cord blood cells there was demonstrated a partial restoration of parameters that characterize left ventricular systolic function, and a significant improvement of impaired heart rate mechanics. No negative effects, complications and side effects have been recorded in short periods of observation after transplantation of cord blood cells.
References
Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation. 2011; 123:e18–e209.
https://doi.org/10.1161/CIR.0b013e3182009701
PMid:21160056 PMCid:PMC4418670
Marelli AJ, Mackie AS, Ionescu-Ittu R, et al. Congenital heart disease in the general population: changing prevalence and age distribution. Circulation. 2007; 115(2):163–172.
https://doi.org/10.1161/CIRCULATIONAHA.106.627224
PMid:17210844
Leor J, Guetta E, Feinberg MS, et al. Human umbilical cord blood-derived CD133+ cells enhance function and repair of the infarcted myocardium. Stem Cells. 2006; 24:772–780.
https://doi.org/10.1634/stemcells.2005-0212
PMid:16195418
Perin EC, Dohmann HF, Borojevic R, et al. Improved exercise capacity and ischemia 6 and 12 months after transendocardial injection of autologous bone marrow mononuclear cells for ischemic cardiomyopathy.Circulation. 2004; 110:II-213–II-218.
https://doi.org/10.1161/01.CIR.0000138398.77550.62
PMid:15364865
Wollert KC, Meyer GP, Lotz J, et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet. 2004; 364:141-148.
https://doi.org/10.1016/S0140-6736(04)16626-9
Strauer B, Yousef M, Schannwell C. The acute and long-term effects of intracoronary stem cell transplantation in 191 patients with chronic heart failure: the STAR-heart study. Eur. J. Heart Fail. 2010; 12:721–729.
https://doi.org/10.1093/eurjhf/hfq095
PMid:20576835
Sucak GT, Ozkurt ZN, Aki Z, et al. Cardiac systolic function in patients receiving hematopoetic stem cell transplantation: risk factors for posttransplantation cardiac toxicity. Transplant Proc. 2008; 40:1586–1590.
https://doi.org/10.1016/j.transproceed.2007.11.077
PMid:18589156
Qazilbash MH, Amjad AI, Qureshi S, et al. Outcome of allogeneic hematopoietic stem cell transplantation in patients with low left ventricular ejection fraction. Biol. Blood Marrow Transplant. 2009; 15:1265–1270.
https://doi.org/10.1016/j.bbmt.2009.06.001
PMid:19747634 PMCid:PMC4112360
Peres E, Levine JE, Khaled YA, et al. Cardiac complications in patients undergoing a reduced-intensity conditioning hematopoietic stem cell transplantation. Bone Marrow Transplant. 2010; 45:149–152.
https://doi.org/10.1038/bmt.2009.97
PMid:19465940 PMCid:PMC3796338
Henning RJ, Burgos JD, Ondrovic L, et al. Human umbilical cord stem cells are attracted to myocardial infarctions. Cell Transplant. 2006; 15:647–658.
https://doi.org/10.3727/000000006783981611
PMid:17176616
Henning RJ, Burgos JD, Vasko M, et al. Human umbilical cord stem cells and myocardial infarction: effect of dose and route of administration on infarct size. Cell Transplant. 2007; 16:907–917.
https://doi.org/10.3727/096368907783338299
PMid:18293889
Henning RJ, Shariff M, Ujwala E, et al. Human cord blood mononuclear cells decrease cytokines and inflammatory cells in acute infarcts. Stem Cells Dev. 2008; 17:1207–1220.
https://doi.org/10.1089/scd.2008.0023
PMid:18393684
Henning RJ, Aufman J, Shariff M, et al. Human umbilical cord stem cells decrease fibrosis and increase cardiac function in cardiomyopathy. Reg. Med. 2010; 5:45–54.
https://doi.org/10.2217/rme.09.71
PMid:20017693
Shiller N, Osipov MA. Klinicheskaja jehokardiografija [Clinical echocardiography]. Moskva, Vidar – Moskow, Vidar, 2005; 344 p.